Vanguard amends Schedule 13G/A after realignment (JAZZ)
Rhea-AI Filing Summary
Jazz Pharmaceuticals PLC: The Vanguard Group files an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock.
The amendment states that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will now report holdings separately in reliance on SEC Release No. 34-39538.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings; reported zero beneficial ownership for Jazz.
The filing lists Amount beneficially owned: 0 and Percent of class: 0%. It attributes the change to an internal realignment on January 12, 2026 and reliance on SEC Release No. 34-39538 for separate reporting by subsidiaries.
Cash‑flow treatment or subsequent holder-level amounts are not included in the excerpt; subsequent filings from Vanguard subsidiaries may show holdings separately.
FAQ
Does The Vanguard Group currently report ownership in JAZZ common stock?
Why did Vanguard amend its Schedule 13G/A for Jazz (JAZZ)?
Does this amendment show any subsidiary holdings of Jazz by Vanguard?
Who signed the amended Schedule 13G/A for Vanguard regarding JAZZ?